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Background: Medication non-adherence continues to be a major challenge facing the
healthcare system. A case is presented of a 48-year-old man with myocardial infarc-
tion who was found to be non-adherent to multiple medications. Conceptual models are
reviewed along with current approaches for assessment and treatment of medication non-
adherence. Design: Case report and literature review. Discussion: A theoretical model for
medication non-adherence built on theTheory of Planned Behavior is presented. Empirical
evidence is reviewed for determinants of non-adherent behavior such as health beliefs and
self-efficacy. Current methods to assess medication non-adherence, including self-report,
pill count, biological drug levels, pharmacy refill, and electronic bottles are summarized
along with their limitations. Finally, an individualized approach for assessment is described
using the case presented and the conceptual framework outlined above. Follow-up for the
patient and potential interventions to improve medication adherence are discussed. Con-
clusion: Despite the challenges, a conceptual framework for medication non-adherence
can guide assessment and treatment. Further research for innovative and effective meth-
ods to detect and treat medication non-adherence is urgently needed to aid clinicians in
treating this pervasive behavioral problem.
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INTRODUCTION
Mr. P is a 48-year-old African American patient with a history
of end-stage renal disease and ischemic cardiomyopathy status
post coronary artery bypass grafting who presented to our hospi-
tal with a myocardial infarction (MI). At admission, he reported
that he had discontinued the aspirin and simvastatin he was sup-
posed to be taking at home, though he later stated that he took
all his medications regularly. He had also intermittently missed
several dialysis sessions, and had missed a scheduled nuclear cardi-
ology test the week prior to admission. During his hospitalization,
he initially agreed to a cardiac catheterization procedure, then
changed his mind and refused. He was also observed eating a
snack high in sodium during a dialysis session despite educa-
tion on sodium restriction. When questioned, he denied that
this occurred. After 2 days in hospital, he was discharged on nine
medications.
At the time of admission, Mr. P consented to participate in a
research project assessing medication adherence. As part of the
research protocol, he answered a brief series of questionnaires
with regards to his socioeconomic background. He was a high
school graduate, and worked as a certified construction worker
until he was diagnosed with renal insufficiency, after which he
became a security guard. He had been unemployed since 2000,
and reported an annual salary of $5,000. He was eligible for and
received Medicaid. Otherwise, he lived alone, but reported having
daily contact with his mother, who also had end-stage renal dis-
ease. He had an 18-years old son, with whom he had no contact
for many years.
BACKGROUND
WHY SHOULD HEALTH PSYCHOLOGISTS CARE?
The pattern of behavior demonstrated by Mr. P raises concerns of
medication non-adherence. Medication non-adherence, defined
here as the failure to take medications as prescribed, is arguably one
of the largest behavioral challenges facing the health care system
today (Osterberg and Blaschke, 2005). Despite several decades of
research that has highlighted the prevalence and negative impact
of medication non-adherence, there remain significant barriers
to adequately detect and treat this pervasive behavioral problem
(Osterberg and Blaschke, 2005; Rasmussen et al., 2007). As will
be discussed below, the complex reasons for medication non-
adherence and the optimal methods to assess it are yet to be
fully elucidated, a process that will require considerable contribu-
tion from the theory, research, and practice of the field of health
psychology.
DETERMINANTS OF NON-ADHERENCE
A number of theoretical models for health behavior have been
specifically adapted for the phenomenon of medication non-
adherence. These include the Health Beliefs Model, that posits
that adherent behavior is predicated upon patients recognizing
the potential adverse consequences of non-adherence; the The-
ory of Reasoned Action, that adds to the Health Beliefs Model by
incorporating subjective norms such as those of family members
and providers that promote adherence; and the Theory of Planned
Behavior, that further incorporates self-efficacy and perceived bar-
riers into the model to account for factors that may or may not
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lie within the patient’s locus of control (Becker, 1974; Ajzen, 1991;
Ryan, 1998). More robust models also recognize additional and
complementary causes of medication non-adherence at various
levels of analysis, including the patient-provider relationship, sys-
temic barriers such as lack of access and financial resources, and the
broader social-economic and cultural context that may impact the
perception of medication efficacy and side-effects. An example of
such a comprehensive schema that combines the theoretical mod-
els mentioned above is provided by Fransen and others (Figure 1).
The model summarizes the multiple potential determinants of
medication non-adherence and how they inform health beliefs
and perceptions of self-efficacy and social norms, to culminate
in the intentional behavior of medication taking (Fransen et al.,
2009).
The empirical literature regarding determinants of non-
adherence has tended to focus on various individual compo-
nents of the comprehensive model. For instance, studies using
pharmacy refill data have reliably demonstrated the impact of
higher medication copayment on non-adherence (Schneeweiss
et al., 2007), while other studies have demonstrated that demo-
graphic and socioeconomic factors including age (both older
and younger), female gender, and lower income status are asso-
ciated with non-adherence (Brenner et al., 2002; Rasmussen
et al., 2007). Medication non-adherence has also been noted
to be particularly problematic in individuals with chronic kid-
ney disease, such as Mr. P (Magacho et al., 2011). Consistent
with the theoretical models described above, health beliefs about
the relative benefit and potential adverse outcomes of medica-
tions have been linked to non-adherence across different dis-
eases (Horne et al., 1999, 2010), as has self-efficacy (Littlefield
et al., 1992). Also of interest to health psychologists in particular
may be the relationship between non-adherence and psycho-
logical traits. For instance, both increased level of hostility and
decreased level of conscientiousness are associated with med-
ication non-adherence (Zugelj et al., 2010; Farrell et al., 2011).
Finally, there is an emerging body of literature highlighting the ele-
vated risk of medication non-adherence in cardiovascular patients
who have depressive symptoms, and it is hypothesized that non-
adherence may be a potential mediator of the known associa-
tion between depression and adverse cardiovascular outcomes
(Brenner et al., 2002; Rieckmann et al., 2006; Compare et al.,
2011).
FIGURE 1 |Theoretical model: determinants of patient adherence.
Adapted from “Which patient-related factors determine self-perceived patient
adherence to prescribed dyspepsia medication?” by Fransen et al. (2009).
Copyright 2009 by G. A. J. Fransen. Reprinted with permission.
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ASSESSMENT OF MEDICATION ADHERENCE
Despite these insights, thus far there remains little consensus on
standardized and practical approaches for assessing medication
non-adherence. In part this is due to the lack of reliable, vali-
dated measurement methods that are useful in both research and
clinical settings. Currently, the most commonly used approaches
include self-report, pill counts, biological drug levels, pharmacy
refill data, and electronic pill bottles, each of which has short-
comings (Osterberg and Blaschke, 2005). Although self-reports of
medication non-adherence can be easily to obtained, both infor-
mally or through use of standardized instruments such as the
Morisky scale (Morisky et al., 2008), the accuracy of this approach
is often questioned due to significant underreporting (Ho et al.,
2009; Mann et al., 2010). Pill counting, a more objective measure,
tends to be more time consuming and fails to capture nuances of
medication taking behavior (Cramer et al., 1989; Osterberg and
Blaschke, 2005). Biological surrogates, such as blood and urine
drug levels or intermediate indices like serum cholesterol or glyco-
sylated hemoglobin that reflect the target of medications, are more
costly and have limited applicability to the broad range of med-
ications that are commonly used (Osterberg and Blaschke, 2005;
Parris et al., 2005). In recent years, the availability of large data-
bases of insurance claims and pharmacy refills has given rise to new
methods for detecting non-adherence. These include measures
such as the medication possession ratio, calculated by dividing the
total number of doses dispensed by the total number of doses that
should have been taken during the days monitored (Taira et al.,
2006; Chan et al., 2010). To date, however, there exist considerable
infrastructural barriers in applying this methodology to individual
patients, given that closed pharmacies and centralized electronic
medical records are only available in a limited number of inte-
grated healthcare systems (Ho et al., 2009). A more promising
approach is the use of devices such as electronic pill bottles, which
are able to capture each instance of medication taking behavior
and allow the analysis of processes by which behavioral tenden-
cies to adhere or not are established (Osterberg and Blaschke, 2005;
Rieckmann et al., 2006). Although the effectiveness of this method
is now well-proven in research settings, issues of cost, ease of
use, and patient acceptance remain barriers for more wide-spread
clinical application.
Because of these limitations, there remains considerable need
for further research on optimal methods to assess medication
non-adherence. As prior research has mostly focused on assess-
ment of non-adherence to individual medications for specific
conditions, there should also be more emphasis on elucidat-
ing potential behavioral patterns of non-adherence that persist
across medication classes. Further research is also needed to
establish a consensus for standardized measurement tools that
can be generalized to clinical settings, and that will be useful
for both patients and providers (Ho et al., 2009). Nonethe-
less, given the high prevalence of non-adherence and the asso-
ciated burden of adverse outcomes, medication non-adherence
should be assessed routinely while awaiting answers from ongoing
research. An example of approaches to and challenges of assess-
ing medication adherence will be discussed using the example
of Mr. P.
DISCUSSION
ASSESSMENT OF MEDICATION NON-ADHERENCE IN RESEARCH
SETTING
Because Mr. P was enrolled in a research protocol, he underwent
a multifaceted assessment of medication adherence behaviors and
potential barriers, using instruments informed by the compre-
hensive model described above. He was first screened for poten-
tial cognitive and psychological conditions that might negatively
impact adherence, using questionnaires that included the Mini-
mental status exam (Folstein et al., 1975), an interview screen for
psychosis and other major mental disorders, the Alcohol Use Dis-
orders Identification Test (AUDIT; Saunders and Aasland, 1987),
and a substance abuse survey. Mr. P screened negative for all of
these. He then completed another set of questionnaires about his
medical history, employment status, education level, and social
support. For depressive symptoms, the Beck Depression Inven-
tory (BDI) version I (Beck et al., 1961) was used because it was
known to predict both mortality and medication non-adherence
in this patient population (Rieckmann et al., 2006; Lichtman et al.,
2008). At the time of his hospitalization as well as 1 month later,
his depressive symptoms were in the moderate range on the BDI
(a score of 14). To specifically assess medication adherence, Mr.
P completed a phone interview at 1 week after discharge during
which he was asked about his ability to pay for his medications and
any potential barriers for filling his aspirin, metoprolol, clopido-
grel, and simvastatin prescriptions. He also completed the Morisky
eight-item self-report medication adherence scale for each of the
four medications (Morisky et al., 2008). At the 1-month visit, he
was assessed with the modified Coronary Artery Risk Develop-
ment in Young Adults (CARDIA) medication adherence scale,
which quantifies the number of days within the past week on
which the monitored medications were taken (Cutter et al., 1991).
Finally, an objective assessment of adherence was obtained using
an electronic pill bottle that had four compartments, one for each
of the monitored medications.
The results of assessment for Mr. P are displayed in Table A1
in Appendix. At the time of discharge, Mr. P reported that he did
not foresee difficulties in obtaining or filling his prescriptions, and
that he was able to afford his medications. At 1 week, he reported
that he had filled all four of his prescriptions. On the Morisky
eight-item self-report medication adherence scale, Mr. P received
a score of 2 out of a possible 8 for all four medications, which
is classified as “poor adherence.” At the 1-month follow-up visit,
he reported on the modified CARDIA medication adherence scale
that he had taken his aspirin, metoprolol, and simvastatin every
day for the past week as prescribed, which was consistent with a
score of 100% for self-reported adherence. However, electronic pill
bottle monitoring demonstrated that his self-reported adherence
rate at 1 month was a vast overestimate, as he only opened the
aspirin compartment of the pillbox on 6 out of 31 days (19.4%),
and the metoprolol and simvastatin compartments on 2 out of
31 days (6.5%) and 3 out of 31 days (9.7%), respectively. He was
also found to have never opened the clopidogrel compartment,
and when questioned, he first insisted that he had filled the clopi-
dogrel prescription, and then eventually admitted that he had in
fact not done so.
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Mr. P had also completed the Beliefs about Medications – Gen-
eral Beliefs – Questionnaire (Horne et al., 1999). He had a high
overall score, indicating distrust. Furthermore, on specific items
he indicated that he strongly agreed that “doctors place too much
trust in medicines. . . if they had more time with patients, they
would prescribe fewer medications.” Also, he indicated that “most
medicines are addictive,” and questioned whether “medicines do
more harm than good.” Taken as a whole, it was apparent that
although Mr. P reported only intermittent non-adherence to his
medications, his medication taking behavior as objectively mea-
sured through electronic pill bottle monitoring was poor, and
he endorsed beliefs about medications being overused and being
potentially harmful that are consistent with his actual behavior.
INDIVIDUALIZED APPROACH TO MEDICATION ASSESSMENT
Although the research protocol described above necessarily differs
from how one might assess medication non-adherence in clin-
ical practice, a number of insights can be drawn and applied.
Current expert consensus recommends that despite the limita-
tions of self-report, asking about medication non-adherence in a
direct and non-judgmental fashion should be a routine compo-
nent of clinical visits (Osterberg and Blaschke, 2005; Ho et al.,
2009). In the case of Mr. P, this likely would have raised high sus-
picion for medication non-adherence, given the different answers
he gave to different providers. Furthermore, confirmation for
medication non-adherence can be achieved by additional meth-
ods such as asking patients to bring medication bottles from
home, or by calling outpatient pharmacy to confirm if important
medications have been filled. When used judiciously for patients
in whom there is heightened concern for non-adherence, these
approaches would not be overly burdensome for most providers.
At the same time, health literacy and health beliefs about spe-
cific medications and medical conditions can be explored, and
self-efficacy and other potential barriers such as costs of medica-
tions and access to the healthcare system should be assessed. This
can be done in an informal manner with open-ended questions.
By helping to uncover reasons for medication non-adherence
that could be promptly addressed, the additional time required
would also likely represent time well-spent to improve patient
outcomes.
OUTCOME OF ASSESSMENT
Because the research protocol was focused on assessment of
medication non-adherence, clinical outcomes were not routinely
collected. Nonetheless, Mr. P gave permission to contact his outpa-
tient cardiologist, Dr. K, after the completion of the study protocol.
More than a year has since passed, and although Mr. P did not have
any further cardiac events, he continued to miss many appoint-
ments. In part because of his non-adherence to medications, his
hypertension remained poorly controlled, and he still reported
intermittent chest pain, with an adverse impact on his quality of
life. There was also concern that his coronary artery disease may
have further progressed. A recent repeat stress test showed new
areas of cardiac ischemia, but despite these high risk features, he
again missed his follow-up cardiology appointment. Dr. K stated
that he has also suspected medication non-adherence, but has been
unable to further engage with Mr. P to make healthy behavioral
changes or to take his medications more regularly. “It is very frus-
trating,” Dr. K said, “but given the limited time and resources, it is
very difficult to find out why he does not take his medications and
convince him otherwise.”
POTENTIAL INTERVENTIONS FOR BEHAVIORAL CHANGE: FROM
THEORY TO PRACTICE
Dr. K’s comments underscore the common perception that chang-
ing non-adherent behavior is a frustratingly difficult endeavor.
Health psychologists, with their expertise and unique insights
into the behavioral determinants of health outcomes, are well-
positioned to facilitate assessment and treatment of complex med-
ication non-adherence issues as exemplified by Mr. P. Although
this review is primarily focused on assessment of non-adherence,
treatment options will be briefly discussed. As a rule, the com-
prehensive conceptual model presented above can be used as the
framework to guide treatment strategies.
Given the core importance of health beliefs and perceived self-
efficacy as key determinants of medication adherence, it is not
surprising that the majority of the interventions that have been
studied have focused on these aspects. For instance, one study of
patients with MI using educational mailings that emphasized the
benefit of beta-blockers and suggested ways to deal with side-
effects showed improved beta-blocker adherence (Smith et al.,
2008). Other interventions to provide similar education and rein-
force self-efficacy have included phone calls (Rudd et al., 2004;
Marquez Contreras et al., 2005) or in-person sessions with phar-
macists (Lee et al., 2006; Murray et al., 2007). In general, more
intensive interventions have tended to be more successful. Con-
siderations of other barriers to adherence have led to additional
approaches, ranging from an ongoing trial to promote adher-
ence through complete elimination of copays (Choudhry et al.,
2008), to technological solutions such as text message reminders
on mobile phones (Lester et al., 2010). For most of these inter-
ventions, however, their applicability and cost-effectiveness in the
general population remain to be determined.
Because no standardized adherence interventions exist, an
understanding of why a particular patient is non-adherent
becomes essential for guiding the choice of treatment. In Mr.
P’s case, for example, it is apparent that a major cause of non-
adherence was his distrust of the medical system, which led him
to discount the efficacy and exaggerate the harms associated with
his medications. It is essential therefore for his providers to engage
with him about his health beliefs so as to improve therapeutic
alignment. Where the resources exist, focused interventions by
health psychologists using counseling techniques such as moti-
vational interviewing or problem solving therapy can contribute
greatly to such efforts (Resnicow et al., 2002). In addition, Mr.
P’s interview revealed that he lived alone and may have mar-
ginal financial resources. Timely referral to a care coordinator or
social worker may help to address potential socioeconomic barri-
ers to medication adherence, by allowing him to obtain increased
services and better access to the healthcare system.
CONCLUDING REMARKS
The case of Mr. P is illustrative of the challenges concerning med-
ication non-adherence that are faced by clinicians and researchers.
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As the discussion demonstrates, the use of a robust conceptual
model such the one outlined by Fransen et al. (2009) can guide
both assessment and treatment of medication non-adherence.
Two additional considerations merit discussion. First, it is impor-
tant to recognize that given the special difficulties of engaging
with non-adherent patients, they are very likely to be under-
represented in clinical studies that require consent and follow-up,
and may be more resistant to interventions that are offered. In
addition, non-adherence is multifaceted, and patients who are
non-adherent to medications may also be less likely to adhere
to other healthy lifestyle choices, creating a negative feedback
between non-adherence and deteriorations in motivation, self-
efficacy, and the ability to adhere. Thus both the prevalence and
adverse impact of medication non-adherence are likely to be
underestimated. To fully address this fundamental issue, con-
siderable insights from the field of health psychology will be
needed to better engage with these patients, and to discover better
methods to detect, understand, and effectively treat medication
non-adherence.
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Table A1 | Outcome of medication adherence assessment for Mr. P.
Measures Details Results
Barriers to adherence Asks whether prescriptions were filled, and if not, reasons
why not (e.g., cost, convenience)
No barriers reported
Morisky scale 8-item self-report medication adherence scale 2/8, indicating poor self-reported medication
adherence
Modified CARDIA scale For each medication, self-reported number of days in the
preceding week on which the medication was taken
7/7 for all medications, indicating excellent
self-reported medication adherenceAspirin
Clopidogrel
Beta-blocker
Statin
Electronic pill bottle For each medication, the number of days on which pill bottle
was opened, divided by total number of days monitored
6/31 (19.4%)
Aspirin 2/31 (6.5%)
Clopidogrel 3/31 (9/7%)
Beta-blocker 0/31 (0%)
Statin Indicating poor medication adherence
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